Literature DB >> 27226281

Induction of Unconventional T Cells by a Mutant Mycobacterium bovis BCG Strain Formulated in Cationic Liposomes Correlates with Protection against Mycobacterium tuberculosis Infections of Immunocompromised Mice.

Steven C Derrick1, Idalia Yabe2, Sheldon Morris3, Siobhan Cowley3.   

Abstract

Earlier studies aimed at defining protective immunity induced by Mycobacterium bovis BCG immunization have largely focused on the induction of antituberculosis CD4(+) and CD8(+) T cell responses. Here we describe a vaccine consisting of a BCGΔmmaA4 deletion mutant formulated in dimethyl dioctadecyl-ammonium bromide (DDA) with d-(+)-trehalose 6,6'-dibehenate (TDB) (DDA/TDB) adjuvant (A4/Adj) that protected TCRδ(-/-) mice depleted of CD4(+), CD8(+), and NK1.1(+) T cells against an aerosol challenge with M. tuberculosis These mice were significantly protected relative to mice immunized with a nonadjuvanted BCGΔmmaA4 (BCG-A4) mutant and nonvaccinated controls at 2 months and 9 months postvaccination. In the absence of all T cells following treatment with anti-Thy1.2 antibody, the immunized mice lost the ability to control the infection. These results indicate that an unconventional T cell population was mediating protection in the absence of CD4(+), CD8(+), NK1.1(+), and TCRγδ T cells and could exhibit memory. Focusing on CD4(-) CD8(-) double-negative (DN) T cells, we found that these cells accumulated in the lungs postchallenge significantly more in A4/Adj-immunized mice and induced significantly greater frequencies of pulmonary gamma interferon (IFN-γ)-producing cells than were seen in the nonvaccinated or nonadjuvanted BCG control groups. Moreover, pulmonary DN T cells from the A4/Adj group exhibited significantly higher IFN-γ integrated median fluorescence intensity (iMFI) values than were seen in the control groups. We also showed that enriched DN T cells from mice immunized with A4/Adj could control mycobacterial growth in vitro significantly better than naive whole-spleen cells. These results suggest that formulating BCG in DDA/TDB adjuvant confers superior protection in immunocompromised mice and likely involves the induction of long-lived memory DN T cells.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27226281      PMCID: PMC4933783          DOI: 10.1128/CVI.00232-16

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  38 in total

1.  The Achilles heel of BCG.

Authors:  Ian M Orme
Journal:  Tuberculosis (Edinb)       Date:  2010-07-24       Impact factor: 3.131

2.  Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response.

Authors:  Malou Henriksen-Lacey; Dennis Christensen; Vincent W Bramwell; Thomas Lindenstrøm; Else Marie Agger; Peter Andersen; Yvonne Perrie
Journal:  J Control Release       Date:  2010-04-08       Impact factor: 9.776

Review 3.  Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines.

Authors:  Bastiaan A Blok; Rob J W Arts; Reinout van Crevel; Christine Stabell Benn; Mihai G Netea
Journal:  J Leukoc Biol       Date:  2015-07-06       Impact factor: 4.962

4.  Mice fed lipid-encapsulated Mycobacterium bovis BCG are protected against aerosol challenge with Mycobacterium tuberculosis.

Authors:  Frank E Aldwell; Lise Brandt; Clare Fitzpatrick; Ian M Orme
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

5.  Effect of cationic liposomes on BCG trafficking and vaccine-induced immune responses following a subcutaneous immunization in mice.

Authors:  Steven C Derrick; Amy Yang; Marcela Parra; Kristopher Kolibab; Sheldon L Morris
Journal:  Vaccine       Date:  2014-11-15       Impact factor: 3.641

6.  Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection.

Authors:  Jes Dietrich; Rolf Billeskov; T Mark Doherty; Peter Andersen
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

7.  Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells.

Authors:  Steven C Derrick; Idalia M Yabe; Amy Yang; Sheldon L Morris
Journal:  Vaccine       Date:  2011-02-21       Impact factor: 3.641

Review 8.  BCG: the challenge continues.

Authors:  P E Fine
Journal:  Scand J Infect Dis       Date:  2001

9.  CD4-CD8- T cells control intracellular bacterial infections both in vitro and in vivo.

Authors:  Siobhán C Cowley; Elizabeth Hamilton; Jeffrey A Frelinger; Jie Su; James Forman; Karen L Elkins
Journal:  J Exp Med       Date:  2005-07-18       Impact factor: 14.307

10.  Immunoregulatory CD4(-)CD8(-) T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer.

Authors:  Erin E Hillhouse; Jean-Sébastien Delisle; Sylvie Lesage
Journal:  Front Immunol       Date:  2013-01-24       Impact factor: 7.561

View more
  3 in total

Review 1.  TCRαβ+ CD4-/CD8- "double negative" T cells in health and disease-implications for the kidney.

Authors:  Andrea M Newman-Rivera; Johanna T Kurzhagen; Hamid Rabb
Journal:  Kidney Int       Date:  2022-04-09       Impact factor: 18.998

Review 2.  Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.

Authors:  Luis O De Serrano; David J Burkhart
Journal:  J Nanobiotechnology       Date:  2017-11-17       Impact factor: 10.435

3.  IL-17 Production from T Helper 17, Mucosal-Associated Invariant T, and γδ Cells in Tuberculosis Infection and Disease.

Authors:  Felicity Coulter; Amy Parrish; Declan Manning; Beate Kampmann; Joseph Mendy; Mathieu Garand; David M Lewinsohn; Eleanor M Riley; Jayne S Sutherland
Journal:  Front Immunol       Date:  2017-10-11       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.